First ‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally‐advanced or metastatic penile squamous cell carcinoma: results of an open label, single‐arm, single‐center, phase 2 study

ConclusionDacomitinib was active and well tolerated in patients with advanced PSCC and may represent an option when combination chemotherapy cannot be administered. Mutations in downstream effectors of EGFR signaling in relation to dacomitinib activity deserve further studies.This article is protected by copyright. All rights reserved.

Source: BJU International - September 1, 2017 Category: Urology & Nephrology Authors: A. Necchi, S. Lo Vullo, F. Perrone, D. Raggi, P. Giannatempo, G. Calareso, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, E. Togliardi, M. Colecchia, A. Busico, A. Gloghini, A. Testi, L. Mariani, R. Salvioni Tags: Original Article Source Type: research